Phase II study of 131I-MIBG with vincristine and 5 days of irinotecan for patients with relapsed or refractory neuroblastoma

Authors :: Fabienne Hollinger
M. Shelly Allen
Yael P. Mosse
Katherine K. Matthay
Melissa A. Bent
Steven G. DuBois
Joan F. Hilton
Randall A. Hawkins
Jesse Courtier
Source :: Journal of Clinical Oncology. 32:10033-10033
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 10033 Background: 131I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical active in neuroblastoma. A previous study demonstrated that MIBG (18 mCi/kg) could be combined with vincristi...

Subjects :: Oncology
Cancer Research
Vincristine
medicine.medical_specialty
business.industry
Phases of clinical research
Pharmacology
medicine.disease
Irinotecan
Refractory
131i mibg
Internal medicine
Neuroblastoma
medicine
business
medicine.drug

Tools